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OBJECTIVES This study sought to assess the incidence of cerebral ischemia in nonselected patients
undergoing neuroprotected carotid angioplasty and stenting (CAS) without preceding
multiple-vessel diagnostic angiography.
BACKGROUND Protection devices to prevent distal embolization during CAS are presently under clinical
investigation. Diffusion-weighted magnetic resonance imaging (MRI) visualizes recent
ischemia of the brain and may aid in assessing the efficacy of protection devices.
METHODS Elective CAS was performed in 42 consecutive patients (15 female, 27 male; mean age, 67 
9 years) using six different types of cerebral protection systems. All patients underwent MRI
of the brain before and after a total of 44 interventions.
RESULTS Placement and retrieval of the devices and stent deployment was achieved in all procedures.
New ischemic foci were seen on postinterventional MRI in 10 cases (22.7%). One patient had
sustained a major stroke, whereas no adverse neurological sequelae were associated with the
other nine procedures. In the latter, one to three foci (maximum area 43.0 mm2) were
detected in cerebral regions subtended by the ipsilateral carotid artery in eight cases and by
the contralateral carotid artery in one case. In the stroke patient, 12 ischemic foci (maximum
area 84.5 mm2) were exclusively located in the contralateral hemisphere. Follow-up MRI at
4.1 months (median, n  7) identified residuals of cerebral ischemia only in this patient.
CONCLUSIONS Neuroprotected CAS is associated in about 25% of cases with predominantly silent cerebral
ischemia. Our findings suggest manipulation of endoluminal equipment in the supraaortic
vessels to be a major risk factor for cerebral embolism during neuroprotected CAS. (J Am
Coll Cardiol 2003;42:1007–13) © 2003 by the American College of Cardiology Foundation
Diffusion-weighted magnetic resonance imaging (MRI) has
been shown to be a highly sensitive tool for the detection of
cerebral ischemia, visualizing recently ischemic regions as
hyperintense areas within minutes of onset (1,2). The
technique has been used as an adjunct to diagnostic cerebral
angiography (3) as well as “unprotected” carotid artery
stenting preceded by three- or four-vessel cerebral angiog-
raphy (4). In both settings, clinically silent cerebral ischemia
was detected with an incidence of 26% and 37%,
respectively.
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Ever since the inception of endovascular treatment of
carotid artery stenoses, interventionists have been concerned
about the risk of stroke secondary to procedure-related
distal embolization (5). However, following the recent
advent of neuroprotective devices to prevent embolic com-
plications, carotid angioplasty and stenting (CAS) has
gained considerable momentum as an alternative to carotid
endarterectomy. The most extensively studied of these
devices has been the PercuSurge GuardWire (Medtronic
AVE, Santa Rosa, California) (6,7). Despite distal occlusion
of the target artery via an inflatable balloon, severe neuro-
logical sequelae have been observed in interventions per-
formed with the device in place (7,8). Technological efforts
presently focus on filter-based protection devices; a feasibil-
ity study of three of these devices has recently been
published (9). In 16 selected patients undergoing CAS
preceded by three- or four-vessel cerebral angiography and
using the AngioGuard filter device (J & J Cordis, Miami
Lakes, Florida) for cerebral protection, clinically silent
ischemia has been detected by diffusion-weighted MRI in
25% (10).
The present study sought to prospectively assess the
incidence of cerebral ischemia, by way of serial diffusion-
weighted MRI, in an unselected, consecutive cohort of
patients subjected to CAS without preceding diagnostic
angiography and with a variety of devices, other than the
GuardWire, utilized for embolic protection.
METHODS
Patients. Between February 14, 2001, and December 31,
2001, 50 consecutive patients underwent elective CAS at
our institution. Forty-two patients who underwent a total of
44 interventions (corresponding to 44 vessels/hemispheres
treated) consented to pre- and postinterventional diffusion-
weighted MRI of the brain. All patients were informed
about the investigational nature of CAS in general and the
use of neuroprotective devices in particular and gave their
written consent. Patient and lesion characteristics are sum-
marized in Table 1.
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Protection devices. Six different cerebral protection sys-
tems were used in this study, selected by availability. They
were the second- and third-generation MedNova Neuro-
Shield (Abbott Vascular, Redwood City, California; n 
14), the FilterWire (Boston Scientific, Maple Grove, Min-
nesota; n  14), the TRAP (ev3, Plymouth, Minnesota;
n  11), the AngioGuard (J & J Cordis; n  2), and the
Distal Protection Device (Medtronic AVE; n  2). These
systems have in common that, before angioplasty, a self-
expanding basket-type filter of varying pore size (80 to 130
m) is deployed distal to the lesion to maintain cerebral
perfusion and capture any debris liberated during the
intervention. In one patient, an “endovascular clamping”
device with two balloons attached to a single guiding
catheter was used (MO.MA, Invatec s.r.l., Roncadelle,
Italy). The balloons can be inflated separately to occlude the
external and common carotid artery and thereby block
antegrade flow across the targeted internal carotid artery
lesion. Close to the proximal balloon, the exit port of the
guiding catheter enables the advancement of angioplasty
equipment and the aspiration of debris.
CAS procedure. Patients received clopidogrel (75 mg/day)
and aspirin (100 mg/day) at least three days preintervention.
In patients not premedicated, a loading dose of clopidogrel
(300 mg) and a bolus of intravenous aspirin (500 mg) were
administered before the intervention. A 100-cm 5F Vitek
catheter (Cook Inc., Bloomington, Indiana) introduced into
the target lesion-related common carotid artery was used for
brachiocephalic angiography. Subsequently, a 0.035-inch
guidewire was introduced through the lumen of the Vitek
catheter into the external carotid artery.
For patients in whom a filter-based protection system was
to be employed, the Vitek catheter was exchanged for a long
7F introducer sheath (Cook Inc.). With the sheath placed in
the common carotid artery and the 0.035-inch guidewire
withdrawn, a bolus of 70 to 100 IU/kg of heparin was
administered and an angiogram taken in anteroposterior
and lateral views to document cerebral blood flow. After
advancement of the introducer sheath towards the carotid
bifurcation, a magnified “worst view” angiogram of the
lesion was taken. Subsequently, the filter systems were
deployed by way of delivery catheters that ranged in crossing
profile between 3.5F (1.16 mm [TRAP]) and 5.5F (1.82
mm [AngioGuard]).
In the remaining patient, the Vitek catheter was with-
drawn and the 11F MO.MA system advanced over the
0.035-inch guidewire. With the distal tip in the external
carotid artery, both balloons were then inflated.
After placement of the protection devices, the lesions
were predilated, supplied with self-expanding stents (pre-
dominantly Wallstents, Boston Scientific), and postdilated
(Bypass Speedy, Boston Scientific). The procedures were
completed by retrieval of the protection systems. Retrieved
filters were flushed with saline solution and their contents
visually assessed. In case of the MO.MA device, 20 ml of
aspirate was withdrawn after pre- and postdilation, filtered
through a 40-m mesh and rinsed with saline solution.
Patients were discharged on a regimen of clopidogrel (75
mg/day for one month) and aspirin (100 mg/day).
MRI. Magnetic resonance imaging scans were obtained
within 24 h before and after the intervention, utilizing a
1.5-T whole-body system (Intera, Philips Medical Systems,
Andover, Massachusetts). Identical single-shot echo-planar
sequences were used at both diagnostic sessions, with the
trace of the diffusion tensor sampled in three orthogonal
acquisitions. All images were reviewed by an experienced
radiologist (J.C.S.). Hyperintense foci on MRI were de-
scribed by their number, location in the brain, and size.
Areas covered by hyperintense foci were calculated using the
formula for an ellipse: /4(long axis)(short axis). Pa-
tients with hyperintense foci on postinterventional MRI
were asked to undergo follow-up MRI (including post-
contrast T1 sequences) three to six months after the
intervention.
Neurological examination. An independent neurologist
established the indication for intervention. The neurological
examination included a calculation of the National Insti-
tutes of Health Stroke Scale and was repeated after inter-
vention and before discharge.
Statistics. Continuous variables are presented by their
mean  1 SD. Comparisons were made utilizing Mann-
Whitney’s U test. A p value 0.05 was considered statisti-
cally significant. Exact 95% confidence intervals (CIs) based
on the binomial distribution were calculated for proportions
(11).
Abbreviations and Acronyms
CAS  carotid angioplasty and stenting
CI  confidence interval
MRI  magnetic resonance imaging
Table 1. Patient and Lesion Characteristics
Patient characteristics (n  42)
Age (yrs) 67  9
Males 27 (64%)
Hypertension 34 (81%)
Diabetes 12 (29%)
Hyperlipidemia 31 (74%)
Smoking, current or ex 23 (55%)
Bilateral disease 13 (31%)
Target lesion (n  44)
Left internal carotid artery 23 (52%)
Left common carotid artery 1 (2%)
Right internal carotid artery 20 (45%)
Lesion characteristics (n  44)
Lesion-related symptoms 6 months 13 (30%)
De novo 43 (98%)
Diameter stenosis (%) 88  9
Lesion length (mm) 13.6  4.9
Ulcerated 19 (43%)
Calcified 12 (27%)
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RESULTS
All protection devices could be used as intended and
procedures were completed successfully in all patients
within 57  23 min. A mean of 184  66 ml of contrast
agent had been administered. One (female) patient, the 31st
in our series, gradually developed dysarthria and amnesic
aphasia within 2 h of an intervention that utilized the
TRAP device; symptoms had not completely resolved at 30
days and the event was classified as a major stroke. Another
female patient (Patient #21 in our series) sustained a
transient ischemic attack (scotoma of ipsilateral eye) for
3.5 h after the 10th of 14 interventions that utilized the
NeuroShield device.
Before intervention, no patient showed signs of recent
cerebral ischemia on MRI. After intervention, MRI exhib-
ited no changes between pre- and postinterventional scans
in 34 cases, including the patient with a transient ischemic
attack.
Hyperintense foci were detected on postinterventional
MRI in nine patients and 10 hemispheres (22.7% [Table 2];
95% CI 11.5% to 37.8%). They were observed in three
patients with bilateral disease (23.1%, 95% CI 5.0% to
53.8%) and six patients with unilateral disease (20.7%, 95%
CI 7.8% to 39.7%). With respect to the symptomatic status
of the lesions treated, positive MRI findings were noted
after three (23.1%) of 13 interventions at symptomatic
lesions (95% CI 5.0% to 53.8%) and 7 (22.6%) of 31
interventions at asymptomatic lesions (95% CI 9.6% to
41.1%). In these 10 procedures, session duration and the
amount of contrast agent administered were not statistically
different from in the other 34 procedures. The mean
baseline diameter stenosis of the targeted lesion was 91 
7% and 86  10% in procedures with positive and negative
MRI findings, respectively (p  0.124); also, no statistically
significant difference was found in the mean crossing profile
of the filter devices used (1.23  0.11 mm vs. 1.32  0.17
mm, respectively; p  0.058).
Eight patients who had undergone nine of these proce-
dures (Patient #5 [Table 2] had bilateral disease and was
treated in two sessions on both left and right carotid artery)
did not experience any periprocedural neurological compli-
cations. The foci were small in number (median 1, range 1
to 3) and had a mean size of 6.9  2.7 mm. In the two
patients with three foci each, these were located in adjacent
tomographic layers (Fig. 1). Cerebral regions containing
ischemic foci were supplied by the targeted (ipsilateral)
carotid artery in eight cases yet by the contralateral circula-
tion in Patient #4. Follow-up MRI scans were obtained in
six of nine cases within a median of 4.2 months and revealed
no persistent ischemic lesions.
In Patient #6 (Table 2), who sustained a major stroke, 12
hyperintense foci distributed over five adjacent tomographic
layers were seen on the postinterventional MRI scan (Fig.
2). The largest focus covered an area of 84.5 mm2, which
was almost twice as large as the largest focus (43.0 mm2)
observed in any of the other positive MRI findings (Table
2). Of note, all foci in this patient were located in the
contralateral hemisphere. On follow-up MRI at 3.7
months, five (42%) of the 12 foci persisted, namely, the two
largest and three of the smaller foci.
DISCUSSION
Utilizing diffusion-weighted MRI, this study showed that
focal ischemic lesions in the brain are seen in about 23% of
patients undergoing neuroprotected CAS exclusively, with-
out extensive preinterventional diagnostic cerebral angiog-
raphy. Neuroprotection was provided by a variety of systems
chosen by availability. The incidence of positive MRI
findings was not dependent on the presence of bilateral
carotid disease nor on the symptomatic status of the lesion
treated. Of the 10 cases with cerebral ischemic lesions, nine
were not associated with overt periprocedural neurological
symptoms, and follow-up MRI showed that the lesions
were reversible. In eight of these nine cases, basket-type
filters had been placed distal to the target lesion and
ischemic foci were all found in the cerebral region supplied
by the targeted carotid artery. In contrast, the one patient in
whom the balloon-based MO.MA system was employed
exhibited focal ischemia in the contralateral cerebellum.
One major periprocedural neurological complication,
namely, a major stroke, was encountered in our series. In
this patient, postinterventional MRI exhibited a markedly
higher number of ischemic foci (12 vs. a median of 1
[maximum 3] in procedures not associated with neurologi-
cal complications), the largest of which was nearly twice as
large as the largest focus on the other positive MRI findings.
Interestingly, in this patient, too, ischemic foci were all
contained in the contralateral hemisphere, whereas the
cerebral region supplied by the targeted carotid artery
remained free of ischemic lesions. Follow-up MRI revealed
persistence of 42% of the ischemic foci at 3.7 months.
The transient ischemic attack, namely, scotoma of the
ipsilateral eye, experienced by one of our patients had no
correlate on MRI, probably because retinal ischemia cannot
be visualized by this technique.
In concordance with previous studies (2,3,12), our find-
ings suggest embolism as the underlying mechanism of
cerebral ischemia. Several scenarios are conceivable.
1) Manipulation of catheters, guidewires, and sheaths
within the supraaortic vasculature before deployment of
the protection device may have resulted in small pieces of
vessel wall to be scraped off. Such pieces would have had
free access to the cerebral circulation. This mechanism is
apparently corroborated by the fact that in two of our
patients ischemic lesions were located in the contralateral
hemisphere. In the MO.MA case, introduction of the
bulky 11F system may have released a particle from the
aortic wall that ended up in an artery supplying the
1009JACC Vol. 42, No. 6, 2003 Schlu¨ter et al.
September 17, 2003:1007–13 Cerebral Ischemia After Carotid Stenting
Table 2. Findings in Patients With Hyperintense Areas on MRI
Patient #1 #2 #3 #4 #5 #5* #6 #7 #8 #9
Location of target lesion left ICA right ICA right ICA left ICA left ICA right ICA right ICA left ICA right ICA right ICA
Lesion history symptomatic asymptomatic asymptomatic asymptomatic symptomatic asymptomatic asymptomatic asymptomatic symptomatic symptomatic
Protection device TRAP TRAP FilterWire MO.MA NeuroShield 2 TRAP TRAP NeuroShield 3 NeuroShield 3 FilterWire
Hyperintense foci
Location left posterior
midbrain
right upper
midbrain
right occipital
lobe
right cerebellum left posterior
midbrain
right occipital
lobe
left frontal lobe
and midbrain
left paraventricular
midbrain
right head of
caudate nucleus
right upper
midbrain
Number 1 3 1 1 3 2 12 1 1 1
Size (mm) 7.8  2.2 9.3  3.2 5.2  2.1 4.8  2.1 6.7  2.5 11.9  4.6 15.6  6.9 8.6  4.7 7.3  4.4 6.1  2.3
6.8  1.7 7.1  2.2 6.9  1.7 6.0  5.1
6.2  1.8 2.3  1.8 5.9  3.2
3.1  2.3
2.6  2.1
2.2  1.9
2.1  2.0
3.2  1.2
2.1  1.7
2.0  1.5
2.4  1.2
1.6  1.5
Area (mm2)† 13.5 23.4 8.6 7.9 13.2 43.0 84.5 31.7 25.2 11.0
Clinical symptoms none none none none none none dysarthria/amnesic
aphasia
none none none
Repeat MRI
Elapsed months 6.7 — 4.6 4.3 2.8 4.1 3.7 — — 1.1
Hyperintense foci none — none none none none 5 — — none
*Second intervention; †maximum area where number 1.
ICA  internal carotid artery; MRI  magnetic resonance imaging; NeuroShield 2  second-generation (fixed-wire) MedNova device; NeuroShield 3  third generation (bare-wire) MedNova device.
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contralateral cerebellum. In the patient who sustained a
stroke, access to the right common carotid artery was
extremely difficult and a considerable amount of time
was spent with attempts to cannulate this vessel using a
variety of endoluminal devices. Most likely, particulate
matter released during introduction and/or withdrawal
of these devices had entered the patient’s brain by way of
the contralateral cervical vasculature.
2) Particulate matter liberated during the intervention may
have passed through the filter pores (100 m in
diameter) and occluded one or more ipsilateral arteries in
the terminal vascular bed of the brain. This mechanism
would likely be related to the composition of the stenotic
plaque and the amount of debris liberated during predi-
lation, stenting, and/or postdilation.
3) Withdrawal of the protection device may have liberated
particles from the device itself (in case of filter systems),
the lesion site, or from vessel walls.
The incidence of cerebral ischemia found in this study
was on the same order of magnitude as that reported in
previous studies involving either diagnostic cerebral angiog-
raphy alone (3) or unprotected and protected CAS preceded
by multiple-vessel cerebral angiography (4,10). In the latter,
Figure 1. Magnetic resonance imaging scans showing three ischemic lesions (arrows in panels B and D) in adjacent tomographic layers of the left posterior
midbrain in Patient #5 (Table 2, first intervention). Corresponding preinterventional MRI scans in panels A and C.
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no distinction could be made as to whether the diagnostic or
the therapeutic part of the intervention was “responsible” for
cerebral embolism; in the former, patients were not system-
ically anticoagulated and may therefore not be strictly
comparable with the patients of our study. However, anti-
coagulation would not prevent the liberation from vessel
walls, and subsequent entry into the cerebral circulation, of
atherosclerotic matter, which has been found to constitute
the debris collected or aspirated from carotid artery lesion
sites (8,9).
Clinical relevance. Clinically, the ischemic lesions de-
tected in our patients remained silent in nine out of 10 cases
and were not related to the targeted carotid artery in the
remaining patient who sustained a major neurological com-
plication. Transcranial Doppler studies have shown that
increased counts of microembolic signals are observed dur-
ing wire crossing of the lesion, predilation, stenting, and
postdilation (13,14). Although it is not known how these
findings relate to cerebral ischemia on diffusion-weighted
MRI, one may assume that microembolic particles possibly
released during predilation, stenting, and/or postdilation
would increase the incidence of cerebral ischemia over that
observed during diagnostic angiography (3). As this was not
the case, neuroprotection in our study had apparently been
effective. With filter devices, lesion crossing as a possible
source of cerebral embolism remains an issue. This may be
related to the degree of stenosis and the crossing profile of
the filter device used. We observed no statistically signifi-
cant differences in the mean degree of stenosis or in the
mean crossing profile between procedures associated with
Figure 2. Postinterventional magnetic resonance imaging scans in Patient #6 (Table 2) showing ischemic lesions (arrows) in several tomographic layers.
The open arrows in panels B and C both denote the largest lesion found in this patient, which extends over two adjacent layers, 5 mm apart.
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positive and those with negative MRI findings, but this is
not conclusive evidence.
Our study therefore suggests that cerebral ischemia was
related to the manipulation of endoluminal equipment in
the supraaortic vasculature before the deployment of the
neuroprotective device. This is primarily supported by the
fact that in two patients cerebral ischemia occurred in the
contralateral hemisphere. Preinterventional transesophageal
echocardiographic or MRI scanning of the aortic arch may
have aided in assessing the embolic risk of the intervention.
In an MRI study on patients undergoing carotid endar-
terectomy, Barth et al. (12) reported an incidence of silent
cerebral ischemia of only 4.2% (2 out of 48 patients). This
significantly lower incidence points to an increased risk of
periprocedural cerebral embolism during CAS as opposed to
carotid endarterectomy. In consideration of the fact that
inevitable interventional maneuvers before actual lesion
treatment may lead to serious neurological complications, it
appears imperative: 1) for the interventionist to be extremely
wary of adverse vessel anatomy, and 2) for the medical
industry to develop less traumatic endoluminal materials to
be used in supraaortic vessels.
The “true” clinical significance of cerebral ischemia that is
not associated with overt neurological symptoms is not
known. Impairment of cognitive function as demonstrated
in patients after cardiac surgery (15) may also be present in
patients with “silent” cerebral ischemia after CAS and
warrants further investigation.
Study limitations. The number of patients in this study
was too small to infer general conclusions on the clinical
efficacy of the neuroprotective devices investigated. The
study lacked a control group of patients. Histological
analysis of filter contents has not been performed; therefore,
no relation of its amount and composition with the inci-
dence, number, and size of ischemic cerebral lesions could
be established. Transcranial Doppler monitoring has not
been performed. To possibly determine the actual interven-
tional maneuver “responsible” for cerebral ischemia, moni-
toring of the vascular access routes to both hemispheres
would be mandatory. However, although continuous Dopp-
ler monitoring is possible, continuous peri-interventional
MRI scanning of the brain is not. Thus, the value of
peri-interventional transcranial Doppler to elucidate
postinterventional MRI findings appears limited. A shorter
follow-up time would have been desirable for a more precise
assessment of the persistence of the ischemic lesions.
Rationale. This study was not designed as a comparative
study aimed at detecting differences in efficacy between
neuroprotective devices. Rather, it is an observational study
on the incidence of procedure-related cerebral ischemia in
consecutive patients undergoing CAS and consenting to
pre- and postinterventional MRI.
Conclusions. Neuroprotected CAS is associated with a
23% incidence of focal, predominantly clinically silent,
cerebral ischemia on diffusion-weighted MRI. This inci-
dence is not different from that reported for diagnostic
cerebral angiography. Cerebral ischemia mostly occurs in
the ipsilateral hemisphere, but the finding, in 2 of 10
patients, of contralateral cerebral ischemia is cause for
concern—particularly because a major neurological compli-
cation not related to the targeted carotid artery was encoun-
tered in one study patient. Our results suggest manipulation
of endoluminal equipment in the supraaortic vasculature to
be a major risk factor for cerebral embolism during neuro-
protected CAS. Conclusive evidence as to the actual mech-
anism of cerebral embolism could not be provided and
warrants further studies to elucidate the safety of CAS, even
when neuroprotection is employed.
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